Company intelligence
RetinAI
Improving R&D of first-in-human drug candidates in pharma. Supercharging clinical trials. Elevating the quality of care.
About RetinAI
RetinAI is a Swiss & US-based software company improving and supporting R&D of first-in-human drug candidates, supercharging management and oversight of clinical trials and enabling the research needed to elevate the quality of care on patients with eye diseases. We achieve this goal by building tools to collect, analyze and to organize health data. Our fundamental belief is that in the future every patient will use drugs alongside a digital application that will enable them and their physicians to better assess the right drug, in the right amount and the right frequency for patients.
Verified activity
Signals from RetinAI
3 published signals
Presence & Recognition
RetinAI is attending EURETINA this year with three scientific sessions on AI-driven analytics and novel therapeutic approaches.
Reported by RetinAI
Presence & Recognition
RetinAI is attending the Euretina and New Orleans, AAO events in Vienna and New Orleans.
Reported by Aunia Grogan
Presence & Recognition
RetinAI is hosting a live session during EURETINA on Thursday, October 1st, 2026, featuring AI-driven imaging and analytics for retinal clinical trials.
Reported by RetinAI